Cargando…
Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit
CRISPR-Cas9 is a revolutionary technology because it is precise, fast and easy to implement, cheap and components are readily accessible. This versatility means that the technology can deliver a timely end product and can be used by many stakeholders. In plant cells, the technology can be applied to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316212/ https://www.ncbi.nlm.nih.gov/pubmed/33721140 http://dx.doi.org/10.1007/s11248-021-00237-y |
_version_ | 1783729828182097920 |
---|---|
author | Jefferson, Osmat Azzam Lang, Simon Williams, Kenny Koellhofer, Deniz Ballagh, Aaron Warren, Ben Schellberg, Bernard Sharma, Roshan Jefferson, Richard |
author_facet | Jefferson, Osmat Azzam Lang, Simon Williams, Kenny Koellhofer, Deniz Ballagh, Aaron Warren, Ben Schellberg, Bernard Sharma, Roshan Jefferson, Richard |
author_sort | Jefferson, Osmat Azzam |
collection | PubMed |
description | CRISPR-Cas9 is a revolutionary technology because it is precise, fast and easy to implement, cheap and components are readily accessible. This versatility means that the technology can deliver a timely end product and can be used by many stakeholders. In plant cells, the technology can be applied to knockout genes by using CRISPR–Cas nucleases that can alter coding gene regions or regulatory elements, alter precisely a genome by base editing to delete or regulate gene expression, edit precisely a genome by homology-directed repair mechanism (cellular DNA), or regulate transcriptional machinery by using dead Cas proteins to recruit regulators to the promoter region of a gene. All these applications can be for: 1) Research use (Non commercial), 2) Uses related product components for the technology itself (reagents, equipment, toolkits, vectors etc), and 3) Uses related to the development and sale of derived end products based on this technology. In this contribution, we present a prototype report that can engage the community in open, inclusive and collaborative innovation mapping. Using the open data at the Lens.org platform and other relevant sources, we tracked, analyzed, organized, and assembled contextual and bridged patent and scholarly knowledge about CRISPR-Cas9 and with the assistance of a new Lens institutional capability, The Lens Report Builder, currently in beta release, mapped the public and commercial innovation pathways of the technology. When scaled, this capability will also enable coordinated editing and curation by credentialed experts to inform policy makers, businesses and private or public investment. |
format | Online Article Text |
id | pubmed-8316212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83162122021-08-13 Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit Jefferson, Osmat Azzam Lang, Simon Williams, Kenny Koellhofer, Deniz Ballagh, Aaron Warren, Ben Schellberg, Bernard Sharma, Roshan Jefferson, Richard Transgenic Res Genome Editing in Plants CRISPR-Cas9 is a revolutionary technology because it is precise, fast and easy to implement, cheap and components are readily accessible. This versatility means that the technology can deliver a timely end product and can be used by many stakeholders. In plant cells, the technology can be applied to knockout genes by using CRISPR–Cas nucleases that can alter coding gene regions or regulatory elements, alter precisely a genome by base editing to delete or regulate gene expression, edit precisely a genome by homology-directed repair mechanism (cellular DNA), or regulate transcriptional machinery by using dead Cas proteins to recruit regulators to the promoter region of a gene. All these applications can be for: 1) Research use (Non commercial), 2) Uses related product components for the technology itself (reagents, equipment, toolkits, vectors etc), and 3) Uses related to the development and sale of derived end products based on this technology. In this contribution, we present a prototype report that can engage the community in open, inclusive and collaborative innovation mapping. Using the open data at the Lens.org platform and other relevant sources, we tracked, analyzed, organized, and assembled contextual and bridged patent and scholarly knowledge about CRISPR-Cas9 and with the assistance of a new Lens institutional capability, The Lens Report Builder, currently in beta release, mapped the public and commercial innovation pathways of the technology. When scaled, this capability will also enable coordinated editing and curation by credentialed experts to inform policy makers, businesses and private or public investment. Springer International Publishing 2021-03-15 2021 /pmc/articles/PMC8316212/ /pubmed/33721140 http://dx.doi.org/10.1007/s11248-021-00237-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Genome Editing in Plants Jefferson, Osmat Azzam Lang, Simon Williams, Kenny Koellhofer, Deniz Ballagh, Aaron Warren, Ben Schellberg, Bernard Sharma, Roshan Jefferson, Richard Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit |
title | Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit |
title_full | Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit |
title_fullStr | Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit |
title_full_unstemmed | Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit |
title_short | Mapping CRISPR-Cas9 public and commercial innovation using The Lens institutional toolkit |
title_sort | mapping crispr-cas9 public and commercial innovation using the lens institutional toolkit |
topic | Genome Editing in Plants |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316212/ https://www.ncbi.nlm.nih.gov/pubmed/33721140 http://dx.doi.org/10.1007/s11248-021-00237-y |
work_keys_str_mv | AT jeffersonosmatazzam mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT langsimon mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT williamskenny mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT koellhoferdeniz mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT ballaghaaron mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT warrenben mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT schellbergbernard mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT sharmaroshan mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit AT jeffersonrichard mappingcrisprcas9publicandcommercialinnovationusingthelensinstitutionaltoolkit |